Yarrow Bioscience (YARW) Financials

Yarrow Bioscience logo
$14.35 +0.00 (+0.03%)
As of 11:12 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Yarrow Bioscience

Annual Income Statements for Yarrow Bioscience

This table shows Yarrow Bioscience's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-4.61 -14 -29 -76 -98 -256 -73 -23 -28 -40 -26
Consolidated Net Income / (Loss)
-4.61 -14 -29 -74 -95 -256 -73 -23 -28 -40 -26
Net Income / (Loss) Continuing Operations
-4.61 -14 -29 -76 -98 -254 -44 -34 -28 -40 -27
Total Pre-Tax Income
-4.61 -14 -30 -74 -95 -256 -45 -34 -28 -40 -27
Total Operating Income
-4.61 -14 -30 -75 -96 -253 -39 -34 -29 -44 -30
Total Gross Profit
0.00 0.67 4.58 3.60 0.44 20 0.93 0.48 0.42 0.50 0.57
Total Revenue
0.00 0.67 4.58 3.60 0.44 21 0.93 0.48 0.42 0.50 0.57
Operating Revenue
0.00 0.67 4.58 3.60 0.44 21 0.93 0.48 0.42 0.50 0.57
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 1.39 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
4.61 15 34 78 96 272 40 35 30 44 30
Selling, General & Admin Expense
1.69 3.75 5.17 14 45 90 20 16 13 13 11
Research & Development Expense
2.92 11 29 64 51 44 20 18 16 31 19
Total Other Income / (Expense), net
0.00 0.00 0.00 -0.94 -2.36 -4.39 -5.75 0.36 1.39 3.83 3.02
Other Income / (Expense), net
- - - 0.94 1.44 - -0.14 0.36 1.39 3.83 3.02
Income Tax Expense
- - - 0.21 -0.18 -0.26 -0.45 0.01 0.00 0.00 0.00
Net Income / (Loss) Discontinued Operations
- - - - - - -29 11 -0.58 -0.03 0.25
Basic Earnings per Share
($0.97) ($2.82) ($5.69) $11.47 $11.22 $7.88 ($25.64) ($7.28) ($2.78) ($0.93) ($0.62)
Weighted Average Basic Shares Outstanding
4.74M 4.99M 5.11M 6.47M 8.49M 32.42M 2.86M 3.19M 10.27M 42.59M 42.77M
Diluted Earnings per Share
($0.97) ($2.82) ($5.69) $11.47 $11.22 $7.88 ($25.64) ($7.28) ($2.78) ($0.93) ($0.62)
Weighted Average Diluted Shares Outstanding
4.74M 4.99M 5.11M 6.47M 8.49M 32.42M 2.86M 3.19M 10.27M 42.59M 42.77M
Weighted Average Basic & Diluted Shares Outstanding
4.74M 4.99M 5.11M 6.47M 8.49M 32.42M 56.17M 3.26M 14.10M 15.21M 33.32M

Quarterly Income Statements for Yarrow Bioscience

This table shows Yarrow Bioscience's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - - - 7.61 - 3.20 11
Net Income / (Loss) Attributable to Common Shareholders
-6.58 -6.19 -6.25 -9.41 -12 -12 -8.61 -5.76 -3.59 -3.01 -9.72
Consolidated Net Income / (Loss)
-6.58 -6.19 -6.25 -9.41 -12 -12 -8.61 -5.76 -3.59 -3.01 -9.72
Net Income / (Loss) Continuing Operations
-6.07 -6.15 -6.24 -9.40 -12 -12 -8.60 -5.75 -3.59 -2.90 -9.72
Total Pre-Tax Income
-6.07 -6.15 -6.24 -9.40 -12 -12 -8.60 -5.75 -3.59 -2.90 -9.72
Total Operating Income
-6.23 -6.83 -7.38 -10 -13 -13 -9.20 -7.54 -3.82 -3.10 -11
Total Gross Profit
0.11 0.08 0.10 0.20 0.12 0.08 0.20 0.07 0.09 0.10 0.00
Total Revenue
0.11 0.08 0.10 0.20 0.12 0.08 0.20 0.07 0.09 0.10 0.00
Total Cost of Revenue
0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
6.35 6.91 7.48 11 13 13 9.40 7.61 3.90 3.20 11
Selling, General & Admin Expense
3.03 3.89 3.77 3.29 2.96 3.17 3.28 2.73 3.09 2.41 5.47
Research & Development Expense
3.32 3.02 3.71 7.31 10 9.68 6.12 4.88 0.82 0.79 5.28
Total Other Income / (Expense), net
0.16 0.68 1.14 1.00 0.93 0.76 0.59 1.80 0.23 0.20 1.02
Interest Expense
- - - - - - - - - - -0.93
Other Income / (Expense), net
0.16 0.68 1.14 1.00 0.93 0.76 0.59 1.80 0.23 0.20 0.09
Basic Earnings per Share
($2.01) ($0.60) ($0.15) ($0.22) ($0.29) ($0.28) ($0.20) ($6.73) ($0.08) ($3.51) ($0.43)
Weighted Average Basic Shares Outstanding
3.28M 10.27M 42.58M 42.59M 42.59M 42.59M 42.67M 855K 42.77M 858K 22.59M
Diluted Earnings per Share
($2.01) ($0.60) ($0.15) ($0.22) ($0.29) ($0.28) ($0.20) ($6.73) ($0.08) ($3.51) ($0.43)
Weighted Average Diluted Shares Outstanding
3.28M 10.27M 42.58M 42.59M 42.59M 42.59M 42.67M 855K 42.77M 858K 22.59M
Weighted Average Basic & Diluted Shares Outstanding
13.96M 14.10M 14.53M 14.75M 14.75M 15.21M 16.66M 25.47M 33.35M 2.67M 15.23M

Annual Cash Flow Statements for Yarrow Bioscience

This table details how cash moves in and out of Yarrow Bioscience's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
44 -40 6.18 12 16 14 -16 -12 -0.30 -11 4.10
Net Cash From Operating Activities
-4.18 -2.27 -28 -69 -73 -137 -56 -29 -25 -34 -33
Net Cash From Continuing Operating Activities
-4.18 -2.27 -28 -69 -73 -137 -56 -29 -25 -34 -33
Net Income / (Loss) Continuing Operations
-4.61 -14 -29 -74 -95 -256 -73 -23 -28 -40 -26
Consolidated Net Income / (Loss)
-4.61 -14 -29 -74 -95 -256 -73 -23 -28 -40 -26
Depreciation Expense
0.00 0.00 0.01 0.32 0.35 0.34 0.11 0.07 0.00 0.00 0.02
Amortization Expense
0.00 0.16 0.07 - - - - 0.00 -0.26 -2.44 -0.78
Non-Cash Adjustments To Reconcile Net Income
0.04 0.57 1.47 4.96 4.75 158 12 -8.34 3.52 3.19 2.31
Changes in Operating Assets and Liabilities, net
0.38 11 -0.69 0.29 17 -40 4.78 2.28 -0.15 5.11 -8.19
Net Cash From Investing Activities
0.00 -38 -15 -12 42 89 1.03 16 -57 23 37
Net Cash From Continuing Investing Activities
0.00 -38 -15 -12 42 89 1.03 16 -57 23 37
Purchase of Property, Plant & Equipment
0.00 -0.03 -0.03 -0.57 -1.06 -0.11 - - 0.00 -0.12 0.00
Purchase of Investments
0.00 -55 -64 -78 -45 - - 0.00 -62 -61 -31
Sale and/or Maturity of Investments
0.00 18 49 66 88 51 1.03 - 0.00 84 68
Net Cash From Financing Activities
48 0.00 49 92 48 62 40 1.65 82 -0.14 -0.14
Net Cash From Continuing Financing Activities
48 0.00 49 92 48 62 40 1.65 82 -0.14 -0.14
Other Financing Activities, net
0.10 0.00 0.03 0.89 0.40 0.17 0.23 -0.03 -0.07 -0.14 -0.14

Quarterly Cash Flow Statements for Yarrow Bioscience

This table details how cash moves in and out of Yarrow Bioscience's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-5.20 15 -12 11 -13 3.61 8.28 -6.16 0.60 -1.71 170
Net Cash From Operating Activities
-5.15 -5.14 -7.98 -8.48 -8.51 -9.00 -11 -11 -4.08 -1.99 -90
Net Cash From Continuing Operating Activities
-5.15 -5.14 -7.98 -8.48 -8.51 -9.00 -11 -11 -4.08 -1.99 -90
Net Income / (Loss) Continuing Operations
-6.58 -6.19 -6.25 -9.41 -12 -12 -8.61 -5.76 -3.59 -3.01 -12
Consolidated Net Income / (Loss)
-6.58 -6.19 -6.25 -9.41 -12 -12 -8.61 -5.76 -3.59 -3.01 -12
Depreciation Expense
- - 0.00 - - - 0.01 0.01 0.01 0.01 -0.01
Non-Cash Adjustments To Reconcile Net Income
0.86 0.93 0.98 0.89 0.74 0.58 0.76 0.53 0.47 0.44 0.61
Changes in Operating Assets and Liabilities, net
0.57 0.38 -1.94 0.66 3.42 2.98 -3.30 -5.37 -0.96 0.58 -78
Net Cash From Investing Activities
- -62 -3.57 19 -4.82 13 20 4.68 4.70 0.30 -5.00
Net Cash From Continuing Investing Activities
- -62 -3.57 19 -4.82 13 20 4.68 4.70 0.30 -5.00
Net Cash From Financing Activities
-0.05 83 -0.01 -0.00 -0.00 -0.13 -0.09 -0.03 -0.02 -0.01 265
Net Cash From Continuing Financing Activities
-0.05 83 -0.01 -0.00 -0.00 -0.13 -0.09 -0.03 -0.02 -0.01 265
Other Financing Activities, net
-0.05 -0.00 -0.01 -0.00 -0.00 -0.13 -0.09 -0.03 -0.02 -0.01 2.93

Annual Balance Sheets for Yarrow Bioscience

This table presents Yarrow Bioscience's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
42 67 140 81 94 67 41 98 67 100
Total Current Assets
32 64 140 76 87 63 38 96 64 100
Cash & Equivalents
4.03 10 50 44 58 42 31 31 20 100
Restricted Cash
- - - 1.26 0.86 0.61 0.07 0.05 - 0.00
Prepaid Expenses
0.63 3.57 3.25 1.56 4.59 4.57 2.30 2.66 2.92 0.01
Plant, Property, & Equipment, net
0.03 0.03 0.15 2.89 0.56 0.35 0.00 0.00 0.11 0.00
Total Noncurrent Assets
10 2.98 0.28 1.86 5.93 3.51 2.48 1.72 2.36 0.41
Other Noncurrent Operating Assets
0.07 - 0.28 1.86 5.93 3.51 2.48 1.72 2.36 0.41
Total Liabilities & Shareholders' Equity
42 67 140 81 94 67 41 98 67 100
Total Liabilities
12 15 9.55 64 56 18 9.35 8.95 15 72
Total Current Liabilities
3.90 7.82 9.54 29 22 18 9.35 7.54 15 72
Accounts Payable
1.53 2.46 3.29 19 4.78 6.51 2.39 1.66 2.71 1.53
Accrued Expenses
0.58 3.56 6.25 3.38 11 8.59 4.38 4.12 9.27 70
Total Noncurrent Liabilities
8.59 6.76 0.01 34 34 0.21 0.00 1.41 0.00 0.00
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
59 109 - - - 0.00 0.21 - - 100
Total Equity & Noncontrolling Interests
-29 -57 130 18 37 49 31 89 52 -71
Total Preferred & Common Equity
-29 -57 130 18 37 49 31 89 52 -71
Total Common Equity
-29 -57 130 18 37 49 31 89 52 -71
Common Stock
0.70 2.21 241 328 604 688 694 780 783 0.00
Retained Earnings
-30 -59 -111 -311 -566 -640 -663 -691 -731 -71

Quarterly Balance Sheets for Yarrow Bioscience

This table presents Yarrow Bioscience's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
19 92 87 76 56 45 26 24 274
Total Current Assets
18 90 84 74 55 44 26 24 274
Cash & Equivalents
15 19 30 16 28 22 25 23 269
Restricted Cash
0.05 0.05 0.05 0.05 - - - - 0.11
Prepaid Expenses
1.76 4.22 5.63 3.30 4.64 4.70 0.86 0.60 4.99
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.11 0.10 0.08 0.08 0.07
Total Noncurrent Assets
1.76 1.45 2.87 2.66 1.40 0.27 0.00 0.00 0.00
Other Noncurrent Operating Assets
1.76 1.45 2.87 2.66 1.40 0.27 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity
19 92 87 76 56 45 26 24 274
Total Liabilities
7.76 8.31 12 13 12 5.84 1.24 1.54 6.51
Total Current Liabilities
6.45 6.93 12 13 12 5.84 1.24 1.54 6.51
Accounts Payable
0.72 2.80 4.52 3.99 3.53 1.41 0.26 0.61 2.13
Accrued Expenses
4.45 3.64 5.07 6.17 6.86 3.58 0.89 0.82 4.38
Total Noncurrent Liabilities
1.31 1.38 0.03 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
0.00 - - - - - - - 0.00
Total Equity & Noncontrolling Interests
12 83 75 64 44 39 25 22 268
Total Preferred & Common Equity
12 83 75 64 44 39 25 22 268
Total Common Equity
12 83 75 64 44 39 25 22 268
Common Stock
697 781 782 783 784 784 786 786 357
Retained Earnings
-685 -698 -707 -719 -740 -746 -761 -764 -90

Annual Metrics And Ratios for Yarrow Bioscience

This table displays calculated financial ratios and metrics derived from Yarrow Bioscience's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 579.82% -21.54% -87.68% 4,638.83% -95.57% -48.76% -11.11% 18.16% 13.77%
EBITDA Growth
0.00% -207.51% -108.32% -149.44% -27.77% -168.07% 84.56% 13.04% 16.93% -50.18% 34.93%
EBIT Growth
0.00% -211.02% -106.48% -149.89% -27.70% -167.43% 84.54% 13.10% 17.86% -42.81% 32.84%
NOPAT Growth
0.00% -211.02% -106.48% -153.07% -28.02% -163.42% 84.59% 11.86% 14.69% -49.15% 31.83%
Net Income Growth
0.00% -205.30% -106.68% -155.07% -28.34% -168.52% 71.31% 68.35% -22.59% -40.00% 33.52%
EPS Growth
0.00% -190.72% -101.77% -155.07% -28.34% -168.52% 71.31% 68.35% 61.81% 66.55% 33.33%
Operating Cash Flow Growth
0.00% 45.85% -1,146.00% -143.30% -6.89% -86.78% 58.88% 48.20% 13.22% -34.06% 2.50%
Free Cash Flow Firm Growth
0.00% 0.00% -1,386.06% -154.48% 12.02% -322.83% 93.39% -90.00% 41.64% -66.04% -12.94%
Invested Capital Growth
0.00% 0.00% 13.43% 42.34% -292.75% 148.65% -118.39% 121.22% -1,143.84% -106.26% 86.82%
Revenue Q/Q Growth
0.00% 0.00% 0.00% -73.20% 106.58% 24.65% -81.17% -35.89% 19.77% 1.62% 0.00%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% -59.66% 2.68% 4.85% 24.96% 2.99% 4.55% -17.02% 0.00%
EBIT Q/Q Growth
0.00% 0.00% 0.00% -62.27% 2.89% 4.84% 24.99% 3.48% 5.42% -17.26% 0.00%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% -64.33% 1.40% 5.76% 25.25% 2.45% 3.79% -15.75% 0.00%
Net Income Q/Q Growth
0.00% 0.00% 0.00% -71.96% 2.55% 5.42% 13.67% 6.54% 11.66% -17.16% 0.00%
EPS Q/Q Growth
0.00% 0.00% 0.00% -71.96% 2.55% 5.42% 13.67% 6.54% 71.66% -16.25% 0.00%
Operating Cash Flow Q/Q Growth
0.00% 0.00% 0.00% -48.39% 12.31% -2.34% 21.41% 15.13% -1.30% -12.83% 0.00%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% 26.03% -5.73% 62.02% -14.63% -20.88% -8.43% 0.00%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% -1.73% -262.79% 97.71% -134.54% -90.25% -14.39% -40.85% 0.00%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 100.00% 100.00% 100.00% 100.00% 93.37% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
0.00% -2,102.37% -644.24% -2,048.18% -21,237.70% -1,201.38% -4,182.28% -7,098.53% -6,633.73% -8,431.54% -4,822.28%
Operating Margin
0.00% -2,126.41% -645.85% -2,083.23% -21,641.76% -1,203.00% -4,179.48% -7,189.73% -6,900.47% -8,709.98% -5,219.12%
EBIT Margin
0.00% -2,126.41% -645.85% -2,057.05% -21,316.70% -1,203.00% -4,193.99% -7,113.63% -6,573.58% -7,944.71% -4,689.82%
Profit (Net Income) Margin
0.00% -2,087.24% -634.57% -2,062.95% -21,484.88% -1,217.40% -7,876.37% -4,865.83% -6,710.38% -7,950.90% -4,646.14%
Tax Burden Percent
100.00% 98.16% 98.25% 100.29% 99.82% 99.90% 164.21% 68.40% 102.08% 100.08% 99.07%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.98% 101.30% 114.37% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -594.84% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -475.08% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 424.56% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
0.00% -47.59% -71.04% -81.20% -128.66% -928.19% -170.28% -57.99% -47.36% -56.57% -66.33%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -1,880.86% 0.00% -6,052.17% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% -34.08% -54.34% -71.52% -85.43% -288.79% -48.57% -62.95% -40.26% -48.37% -55.08%
Return on Assets (ROA)
0.00% -33.45% -53.39% -71.73% -86.10% -292.24% -91.21% -43.06% -41.10% -48.40% -54.57%
Return on Common Equity (ROCE)
0.00% 47.39% 75.05% -32.60% -128.66% -928.19% -170.28% -57.84% -47.28% -56.57% -66.33%
Return on Equity Simple (ROE_SIMPLE)
0.00% 47.78% 50.98% -56.88% -541.55% -681.64% -150.77% -74.39% -32.06% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-3.23 -10 -21 -52 -67 -177 -27 -24 -20 -31 -21
NOPAT Margin
0.00% -1,488.49% -452.10% -1,458.26% -15,149.23% -842.10% -2,925.64% -5,032.81% -4,830.33% -6,096.99% -3,653.39%
Net Nonoperating Expense Percent (NNEP)
0.00% -19.53% -16.11% -21.88% -31.73% -235.49% -119.76% 1.95% -12.83% -12.00% -12.50%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -23.08% -58.65% -75.00%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 6.63% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 556.53% 112.79% 389.79% 10,183.75% 426.54% 2,180.34% 3,435.43% 3,154.48% 2,633.13% 1,944.21%
R&D to Revenue
0.00% 1,669.88% 633.06% 1,793.44% 11,558.01% 207.37% 2,099.14% 3,854.30% 3,845.99% 6,176.85% 3,374.91%
Operating Expenses to Revenue
0.00% 2,226.41% 745.85% 2,183.23% 21,741.76% 1,296.37% 4,279.48% 7,289.73% 7,000.47% 8,809.98% 5,319.12%
Earnings before Interest and Taxes (EBIT)
-4.61 -14 -30 -74 -94 -253 -39 -34 -28 -40 -27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-4.61 -14 -30 -74 -94 -252 -39 -34 -28 -42 -27
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.73 6.33 7.07 1.12 0.28 0.37 0.95 0.53
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.73 6.33 7.07 1.12 0.28 0.37 0.95 0.53
Price to Revenue (P/Rev)
0.00 176.56 25.97 26.62 251.21 12.64 58.63 18.25 76.70 98.64 25.92
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 21.30 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 202.78 36.20 0.00 159.47 11.38 12.60 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 78.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 1.86 0.88 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 1.86 0.88 0.00 0.00 0.00 0.00 0.00
Financial Leverage
0.00 -1.40 -1.27 -1.09 -1.20 -1.22 -0.89 -1.02 -1.03 -1.10 -1.13
Leverage Ratio
0.00 1.42 1.33 1.13 1.49 3.18 1.87 1.35 1.15 1.17 1.22
Compound Leverage Factor
0.00 1.42 1.33 1.13 1.51 3.22 2.14 1.35 1.15 1.17 1.22
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 65.06% 46.94% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 65.06% 46.94% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 199.59% 209.07% 0.00% 0.00% 0.00% 0.00% 0.67% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% -99.59% -109.07% 100.00% 34.94% 53.06% 100.00% 99.33% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 -0.35 -0.13 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.43 0.10 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 -0.35 -0.13 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 -0.49 -0.19 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.61 0.15 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 -0.49 -0.19 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.00 4.39 3.27 4.30 -7.45 -13.45 -12.68 -24.09 -7.58 -14.36 -33.28
Noncontrolling Interest Sharing Ratio
0.00% 199.59% 205.64% 59.85% 0.00% 0.00% 0.00% 0.26% 0.18% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.00 8.08 8.17 14.62 2.61 4.01 3.47 4.10 12.73 4.35 12.53
Quick Ratio
0.00 7.92 7.71 14.28 2.46 3.42 2.74 3.31 12.37 4.15 12.11
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 1.73 -22 -57 -50 -211 -14 -27 -15 -26 -29
Operating Cash Flow to CapEx
0.00% -7,306.45% -104,525.93% -12,327.47% -7,209.63% -121,311.50% 0.00% 0.00% 0.00% -29,035.90% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 -54.20 -48.08 -2.49 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 -79.69 -31.23 -10.05 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 -80.79 -31.25 -10.05 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.02 0.08 0.03 0.00 0.24 0.01 0.01 0.01 0.01 0.01
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 2.63 0.08 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.32 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 24.96 166.62 41.32 0.29 12.21 2.05 0.00 0.00 0.00 5.62
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.12 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 138.69 4,587.40 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 1,148.49 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 3,163.86 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 -1,876.67 4,587.40 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
0.00 -12 -10 -5.87 -23 11 -2.06 0.44 -4.57 -9.43 -1.24
Invested Capital Turnover
0.00 -0.11 -0.42 -0.45 -0.03 -3.54 0.20 -0.59 -0.21 -0.07 -0.11
Increase / (Decrease) in Invested Capital
0.00 -12 1.58 4.31 -17 34 -13 2.50 -5.01 -4.86 8.19
Enterprise Value (EV)
0.00 137 166 -41 71 239 12 -22 -61 -12 -14
Market Capitalization
119 119 119 96 111 265 55 8.71 33 49 15
Book Value per Share
$0.00 ($5.90) ($11.17) $5.61 $0.73 $0.22 $0.91 $0.54 $6.36 $3.53 $1.09
Tangible Book Value per Share
$0.00 ($5.90) ($11.17) $5.61 $0.73 $0.22 $0.91 $0.54 $6.36 $3.53 $1.09
Total Capital
0.00 30 52 130 50 71 49 31 89 52 28
Total Debt
0.00 0.00 0.00 0.00 33 33 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 33 33 0.00 0.00 0.00 0.00 0.00
Net Debt
0.00 -41 -62 -136 -41 -26 -43 -31 -93 -62 -29
Capital Expenditures (CapEx)
0.00 0.03 0.03 0.56 1.02 0.11 0.00 0.00 0.00 0.12 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -3.27 -3.46 -6.29 -26 6.05 2.13 -2.05 -4.88 -12 -1.39
Debt-free Net Working Capital (DFNWC)
0.00 28 56 130 47 65 45 29 88 50 28
Net Working Capital (NWC)
0.00 28 56 130 47 65 45 29 88 50 28
Net Nonoperating Expense (NNE)
1.38 4.04 8.36 22 28 79 46 -0.80 7.97 9.29 5.66
Net Nonoperating Obligations (NNO)
0.00 -41 -62 -136 -41 -26 -51 -31 -93 -62 -29
Total Depreciation and Amortization (D&A)
0.00 0.16 0.07 0.32 0.35 0.34 0.11 0.07 -0.26 -2.44 -0.76
Debt-free, Cash-free Net Working Capital to Revenue
0.00% -485.31% -75.45% -175.08% -5,931.83% 28.81% 228.46% -428.72% -1,151.42% -2,374.85% -244.39%
Debt-free Net Working Capital to Revenue
0.00% 4,100.45% 1,223.13% 3,614.91% 10,629.35% 311.98% 4,831.58% 6,064.99% 20,854.95% 9,903.79% 4,844.74%
Net Working Capital to Revenue
0.00% 4,100.45% 1,223.13% 3,614.91% 10,629.35% 311.98% 4,831.58% 6,064.99% 20,854.95% 9,903.79% 4,844.74%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($69.84) ($203.04) ($409.68) ($170.64) ($222.48) $141.84 $25.56 ($7.28) ($2.78) ($0.93) ($0.62)
Adjusted Weighted Average Basic Shares Outstanding
65.77K 69.27K 319.14K 323.03K 339.43K 2.85M 2.86M 3.19M 10.27M 42.59M 42.77M
Adjusted Diluted Earnings per Share
($69.84) ($203.04) ($409.68) ($170.64) ($222.48) $141.84 $25.56 ($7.28) ($2.78) ($0.93) ($0.62)
Adjusted Weighted Average Diluted Shares Outstanding
65.77K 69.27K 319.14K 323.03K 339.43K 2.85M 2.86M 3.19M 10.27M 42.59M 42.77M
Adjusted Basic & Diluted Earnings per Share
($69.84) ($203.04) ($409.68) ($170.64) ($222.48) $141.84 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
65.77K 69.27K 70.95K 300.95K 330.82K 1.80M 3.12M 3.26M 14.10M 15.21M 33.32M
Normalized Net Operating Profit after Tax (NOPAT)
-3.23 -10 -21 -52 -67 -139 -27 -24 -20 -31 -21
Normalized NOPAT Margin
0.00% -1,488.49% -452.10% -1,458.26% -15,149.23% -660.89% -2,925.64% -5,032.81% -4,830.33% -6,096.99% -3,653.39%
Pre Tax Income Margin
0.00% -2,126.41% -645.85% -2,057.05% -21,524.61% -1,218.63% -4,796.56% -7,113.63% -6,573.58% -7,944.71% -4,689.82%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 -102.53 -57.53 -6.96 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 -72.87 -40.27 -4.86 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 -103.64 -57.55 -6.96 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 -73.97 -40.30 -4.86 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Yarrow Bioscience

This table displays calculated financial ratios and metrics derived from Yarrow Bioscience's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
3,279,971.00 13,957,324.00 14,098,888.00 14,528,247.00 14,749,397.00 14,751,433.00 15,209,862.00 16,664,892.00 33,323,171.00 33,352,858.00 2,669,746.00
DEI Adjusted Shares Outstanding
3,279,971.00 13,957,324.00 14,098,888.00 14,528,247.00 14,749,397.00 14,751,433.00 15,209,862.00 16,664,892.00 33,323,171.00 667,057.00 2,669,746.00
DEI Earnings Per Adjusted Shares Outstanding
-2.01 -0.44 -0.44 -0.65 -0.82 -0.82 -0.57 -0.35 -0.11 -4.51 -3.64
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-31.74% 1,166.67% -1.01% 46.67% 6.14% 10.53% 106.12% -65.15% -57.43% 40.58% 0.00%
EBITDA Growth
33.17% 18.94% -25.05% 0.27% -108.58% -95.97% -27.12% 40.52% 59.68% 51.37% 0.00%
EBIT Growth
34.40% 20.61% -11.21% 6.41% -100.25% -95.25% -37.85% 38.83% 58.33% 49.56% 0.00%
NOPAT Growth
33.20% 14.44% -25.62% -0.76% -109.99% -86.94% -24.62% 27.45% 58.51% 58.87% 0.00%
Net Income Growth
30.39% 37.78% -11.15% 6.48% -84.64% -94.28% -37.80% 38.82% 58.37% 47.75% 0.00%
EPS Growth
31.63% 80.77% 91.38% 92.88% 85.57% 53.33% -33.33% 40.91% 60.00% 47.75% 0.00%
Operating Cash Flow Growth
27.69% -6.78% -45.69% 11.41% -65.18% -75.18% -43.60% -27.36% 64.39% 81.56% 0.00%
Free Cash Flow Firm Growth
181.69% 102.82% -246.10% -524.61% -256.74% -1,887.56% 54.05% -4.90% -190.60% 73.39% 0.00%
Invested Capital Growth
-188.98% -1,143.84% 31.57% 4.40% -67.50% -106.26% -133.11% 76.66% 95.26% -12.81% 0.00%
Revenue Q/Q Growth
-15.56% -33.33% 28.95% 102.04% -38.89% -30.58% 140.48% -65.84% 0.00% 12.79% -100.00%
EBITDA Q/Q Growth
39.52% -5.52% -9.55% -42.65% -26.49% 0.86% 28.94% 33.25% 0.00% 19.49% -267.99%
EBIT Q/Q Growth
39.52% -1.32% -1.46% -50.54% -29.40% 1.21% 28.37% 33.20% 0.00% 19.14% -267.33%
NOPAT Q/Q Growth
39.58% -9.58% -8.04% -40.87% -25.92% 2.45% 27.98% 18.00% 0.00% 18.71% -246.33%
Net Income Q/Q Growth
34.54% 6.01% -0.99% -50.52% -29.25% 1.11% 28.37% 33.17% 0.00% 16.12% -223.38%
EPS Q/Q Growth
34.95% 70.15% 75.00% -46.67% -31.82% 3.45% 28.57% 35.00% 0.00% 16.12% 87.75%
Operating Cash Flow Q/Q Growth
46.19% 0.29% -55.36% -6.28% -0.34% -5.75% -27.36% 5.74% 0.00% 51.19% -4,415.91%
Free Cash Flow Firm Q/Q Growth
135.81% -94.47% -2,895.01% -16.41% 12.96% 36.88% 28.16% -165.78% 0.00% 75.66% 100.00%
Invested Capital Q/Q Growth
-16.56% -14.39% 42.39% -24.45% -104.24% -40.85% 34.89% 87.54% 0.00% -196.56% -67.67%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin
-5,325.44% -8,428.95% -7,161.22% -5,056.06% -10,465.29% -14,945.24% -4,416.34% -8,630.43% -4,182.56% -2,985.57% 0.00%
Operating Margin
-5,468.42% -8,988.16% -7,530.61% -5,250.51% -10,819.01% -15,202.38% -4,552.97% -10,930.43% -4,437.21% -3,197.94% 0.00%
EBIT Margin
-5,325.44% -8,093.42% -6,368.37% -4,744.95% -10,047.11% -14,297.62% -4,258.91% -8,328.99% -4,168.60% -2,988.66% 0.00%
Profit (Net Income) Margin
-5,775.44% -8,142.11% -6,376.53% -4,750.51% -10,047.11% -14,311.90% -4,262.87% -8,340.58% -4,168.60% -3,100.00% 0.00%
Tax Burden Percent
108.45% 100.60% 100.13% 100.12% 100.00% 100.10% 100.09% 100.14% 100.00% 103.73% 100.00%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 91.31%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-5,475.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
-5,466.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
5,413.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-61.16% -47.36% -52.97% -61.70% -90.62% -56.57% -66.19% -67.77% -62.40% -61.40% 0.00%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-56.98% -49.57% -42.44% -41.32% -103.77% -87.04% -34.80% -60.36% -45.99% -42.17% 0.00%
Return on Assets (ROA)
-61.79% -49.87% -42.50% -41.37% -103.77% -87.13% -34.83% -60.44% -45.99% -43.74% 0.00%
Return on Common Equity (ROCE)
-61.16% -47.28% -52.97% -61.70% -90.62% -56.57% -66.19% -67.77% -62.40% -61.40% 0.00%
Return on Equity Simple (ROE_SIMPLE)
-279.96% 0.00% -34.88% 0.00% -53.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-4.36 -4.78 -5.17 -7.28 -9.16 -8.94 -6.44 -5.28 -2.67 -2.17 -7.52
NOPAT Margin
-3,827.89% -6,291.71% -5,271.43% -3,675.35% -7,573.31% -10,641.67% -3,187.08% -7,651.30% -3,106.05% -2,238.56% 0.00%
Net Nonoperating Expense Percent (NNEP)
-8.69% -2.26% -1.86% -4.31% -6.98% -3.98% -3.19% -0.81% -2.43% -2.67% -0.82%
Return On Investment Capital (ROIC_SIMPLE)
- -5.39% -6.20% -9.72% - -17.16% -14.59% -13.58% -10.84% -9.84% -2.81%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
2,657.89% 5,111.84% 3,846.94% 1,660.61% 2,449.59% 3,773.81% 1,621.29% 3,956.52% 3,587.21% 2,485.57% 0.00%
R&D to Revenue
2,910.53% 3,976.32% 3,783.67% 3,689.90% 8,469.42% 11,528.57% 3,031.68% 7,073.91% 950.00% 812.37% 0.00%
Operating Expenses to Revenue
5,568.42% 9,088.16% 7,630.61% 5,350.51% 10,919.01% 15,302.38% 4,652.97% 11,030.43% 4,537.21% 3,297.94% 0.00%
Earnings before Interest and Taxes (EBIT)
-6.07 -6.15 -6.24 -9.40 -12 -12 -8.60 -5.75 -3.59 -2.90 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-6.07 -6.41 -7.02 -10 -13 -13 -8.92 -5.96 -3.60 -2.90 -11
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.15 0.37 0.52 0.38 0.44 0.95 0.54 0.71 0.81 0.56 0.22
Price to Tangible Book Value (P/TBV)
1.15 0.37 0.52 0.38 0.44 0.95 0.54 0.71 0.81 0.56 0.22
Price to Revenue (P/Rev)
37.43 76.70 102.33 58.89 56.25 98.64 39.72 57.77 43.86 25.40 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.99 -1.03 -1.06 -1.07 -1.14 -1.10 -1.07 -1.04 -1.09 -1.03 -1.01
Leverage Ratio
1.28 1.15 1.16 1.21 1.27 1.17 1.16 1.15 1.20 1.12 1.02
Compound Leverage Factor
1.28 1.15 1.16 1.21 1.27 1.17 1.16 1.15 1.20 1.12 0.94
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-49.09 -6.85 -6.66 -9.32 -11.46 -12.99 -16.77 -19.89 -30.83 -39.83 0.00
Noncontrolling Interest Sharing Ratio
0.00% 0.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.72 12.73 13.02 7.13 5.81 4.35 4.47 7.60 20.86 15.26 42.08
Quick Ratio
2.43 12.37 12.40 6.64 5.54 4.15 4.09 6.79 20.17 14.87 41.29
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
4.13 0.23 -6.38 -7.43 -6.47 -4.08 -2.93 -7.79 -8.52 -2.07 0.00
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00
Accounts Receivable Turnover
0.98 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.75 5.36 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
371.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
371.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-4.00 -4.57 -2.63 -3.28 -6.70 -9.43 -6.14 -0.77 -0.29 -0.86 -1.45
Invested Capital Turnover
1.43 -0.21 -0.13 -0.14 -0.09 -0.07 -0.14 -0.24 -0.14 -0.59 0.00
Increase / (Decrease) in Invested Capital
-8.49 -5.01 1.22 0.15 -2.70 -4.86 -3.51 2.51 5.85 -0.10 0.00
Enterprise Value (EV)
-2.25 -61 -43 -50 -43 -12 -26 -12 -5.02 -11 -209
Market Capitalization
13 33 43 29 28 49 24 27 20 12 60
Book Value per Share
$3.51 $6.36 $5.91 $5.15 $4.31 $3.53 $2.90 $2.33 $0.74 $0.66 $100.20
Tangible Book Value per Share
$3.51 $6.36 $5.91 $5.15 $4.31 $3.53 $2.90 $2.33 $0.74 $0.66 $100.20
Total Capital
12 89 83 75 64 52 44 39 25 22 268
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-16 -93 -86 -78 -70 -62 -50 -40 -25 -23 -269
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-4.44 -4.88 -2.71 -6.13 -9.36 -12 -7.65 -1.14 -0.38 -0.94 -1.52
Debt-free Net Working Capital (DFNWC)
11 88 83 72 61 50 43 39 25 22 267
Net Working Capital (NWC)
11 88 83 72 61 50 43 39 25 22 267
Net Nonoperating Expense (NNE)
2.22 1.41 1.08 2.13 2.99 3.08 2.17 0.48 0.91 0.84 2.20
Net Nonoperating Obligations (NNO)
-16 -93 -86 -78 -70 -62 -50 -40 -25 -23 -269
Total Depreciation and Amortization (D&A)
0.00 -0.26 -0.78 -0.62 -0.51 -0.54 -0.32 -0.21 -0.01 0.00 -0.01
Debt-free, Cash-free Net Working Capital to Revenue
-1,254.24% -1,151.42% -640.90% -1,260.29% -1,898.17% -2,374.85% -1,264.46% -239.50% -82.60% -195.23% 0.00%
Debt-free Net Working Capital to Revenue
3,124.86% 20,854.95% 19,691.02% 14,819.34% 12,347.67% 9,903.79% 7,044.96% 8,089.71% 5,408.15% 4,561.00% 0.00%
Net Working Capital to Revenue
3,124.86% 20,854.95% 19,691.02% 14,819.34% 12,347.67% 9,903.79% 7,044.96% 8,089.71% 5,408.15% 4,561.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($2.01) ($0.60) ($0.15) ($0.22) ($0.29) ($0.28) ($0.20) ($0.13) ($0.08) ($3.51) ($0.43)
Adjusted Weighted Average Basic Shares Outstanding
3.28M 10.27M 42.58M 42.59M 42.59M 42.59M 42.67M 42.76M 42.77M 858K 22.59M
Adjusted Diluted Earnings per Share
($2.01) ($0.60) ($0.15) ($0.22) ($0.29) ($0.28) ($0.20) ($0.13) ($0.08) ($3.51) ($0.43)
Adjusted Weighted Average Diluted Shares Outstanding
3.28M 10.27M 42.58M 42.59M 42.59M 42.59M 42.67M 42.76M 42.77M 858K 22.59M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($0.60) $0.00 $0.00 $0.00 ($0.28) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
13.96M 14.10M 14.53M 14.75M 14.75M 15.21M 16.66M 25.47M 33.35M 2.67M 15.23M
Normalized Net Operating Profit after Tax (NOPAT)
-4.36 -4.78 -5.17 -7.28 -9.16 -8.94 -6.44 -5.28 -2.67 -2.17 -7.52
Normalized NOPAT Margin
-3,827.89% -6,291.71% -5,271.43% -3,675.35% -7,573.31% -10,641.67% -3,187.08% -7,651.30% -3,106.05% -2,238.56% 0.00%
Pre Tax Income Margin
-5,325.44% -8,093.42% -6,368.37% -4,744.95% -10,047.11% -14,297.62% -4,258.91% -8,328.99% -4,168.60% -2,988.66% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Data note: The supplied filings identify the company as VYNE Therapeutics Inc. (NASDAQ: VYNE), rather than Yarrow Bioscience (NASDAQ: YARW). The analysis below is based on the financial data provided and should be verified against the intended issuer.

VYNE’s second-quarter 2026 results show improvement from the prior-year quarter, although the company remains unprofitable and continues to consume cash. Revenue increased to $97,000 from $69,000 in Q2 2025, while the net loss narrowed to $3.0 million from $5.8 million. The improvement was driven primarily by lower research and development spending and reduced selling, general and administrative expenses.

  • Operating losses narrowed materially. The Q2 2026 operating loss was $3.1 million, compared with a $7.5 million loss in Q2 2025 and a $13.1 million loss in Q3 2024.
  • Net losses have improved year over year. The consolidated loss declined to $3.0 million in Q2 2026 from $5.8 million in Q2 2025. The Q1 2026 loss was $3.6 million, indicating sequential improvement as well.
  • Operating expenses were reduced. Total operating expenses fell to $3.2 million in Q2 2026 from $7.6 million in Q2 2025. Research and development expense declined to $788,000 from $4.9 million, while SG&A decreased to $2.4 million from $2.7 million.
  • Operating cash burn improved. Cash used in operating activities was $2.0 million in Q2 2026, substantially below $10.8 million in Q2 2025 and $8.5 million in Q3 2024.
  • The balance sheet remains lightly leveraged. Total liabilities were $1.5 million at June 30, 2026, compared with $5.8 million at June 30, 2025. There were no reported noncurrent liabilities in the latest quarter.
  • Liquidity currently exceeds near-term obligations. Cash and equivalents totaled $22.9 million against current liabilities of $1.5 million at the end of Q2 2026, implying substantial short-term balance-sheet coverage.
  • Revenue remains very small and volatile. Quarterly revenue has generally ranged from approximately $69,000 to $202,000 across the supplied periods. Although Q2 2026 revenue rose 41% year over year, the absolute level is not yet sufficient to support the company’s cost structure.
  • Cash holdings have shifted from investments into cash. Short-term investments declined from $17.6 million in Q2 2025 to zero in Q2 2026, while cash remained high at $22.9 million. This may improve accessibility of funds, but it also leaves the company with fewer separately reported investment assets.
  • The company continues to report recurring losses. Every supplied income statement shows a net loss, and retained earnings were negative $764.2 million at June 30, 2026, reflecting substantial cumulative losses.
  • Cash is still declining despite lower operating burn. Cash and equivalents fell from $24.6 million at March 31, 2026, to $22.9 million at June 30, 2026. The company reported a $1.7 million quarterly reduction in cash and received only minimal financing proceeds.

Overall, the financial trend is mixed but improving operationally. Expense reductions have narrowed both operating and net losses, and the company has a comparatively strong liquidity position with limited liabilities. However, revenue remains negligible, profitability has not been reached, and continued operating cash outflows mean the cash balance will require ongoing monitoring. Investors should also reconcile the unusually large changes in reported share counts across periods, as the filings include restated figures and may reflect corporate actions such as a reverse split.

11/19/26 11:12 AM ETAI Generated. May Contain Errors.

Yarrow Bioscience Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Yarrow Bioscience's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Over the last 10 years, Yarrow Bioscience's net income changed from -$4.61 million in 2015 to -$26.48 million in 2025, a change of -474.7%. View Yarrow Bioscience's forecast to see where analysts expect Yarrow Bioscience to go next.

Yarrow Bioscience's total operating income in 2025 was -$29.75 million, based on the following breakdown:
  • Total Gross Profit: $570 thousand
  • Total Operating Expenses: $30.32 million

Over the last 10 years, Yarrow Bioscience's total revenue changed from $0.00 in 2015 to $570 thousand in 2025, a change of 57,000,000.0%.

In the past 12 quarters, Yarrow Bioscience's cash and equivalents has ranged from $15.45 million in Q3 2023 to $268.86 million in Q3 2026, and is currently $268.86 million as of their latest financial filing in Q3 2026.

Yarrow Bioscience had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2015.

Over the last 10 years, Yarrow Bioscience's book value per share changed from 0.00 in 2015 to 1.09 in 2025, a change of 109.0%.



Financial statements for NASDAQ:YARW last updated on 11/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners